Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients

Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients (EMINENT Study)

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02254824

Enrollment

300

Registered

2014-10-02

Start date

2013-10-31

Completion date

2016-10-31

Last updated

2014-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Xuezhikang, atorvastatin

Brief summary

The purpose of EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin in hypertensive patients at low/moderate cardiovascular risk.

Detailed description

EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin on vascular function protection in hypertensive patients at low/moderate cardiovascular risk.

Interventions

DRUGXuezhikang

Xuezhikang

DRUGAtorvastatin

Atorvastatin

BEHAVIORALLifestyle modification

Lifestyle modification

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* All patients must meet the hypertension with low or moderate cardiovascular risk following 2010 Guidelines for prevention and treatment of hypertension in China

Exclusion criteria

* Secondary Hypertension * Women who are pregnant or lactating * History of mental instability, or major psychiatric illness not adequately controlled and stable on therapy * Type 2 Diabetes * Active liver disease or impaired liver function tests * Impaired renal function * Uncontrolled cardiac arrhythmia * Patient who is unable to give informed consent * Any condition or situation, which in the opinion of the investigator, might pose a risk to the patient or confound the results of the study

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the Flow Mediated Dilatation (FMD)	1 year

Secondary

Measure	Time frame
the carotid - femoral Pulse Wave Velocity (cf-PWV),	1 year
inflammatory markers	1 year
lipid profiles	1 year

Countries

China

Contacts

Primary ContactAimin - Dang, Doctor

amdang@fuwaihospital.org0086-10-88398155

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026